JP6857185B2 - 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法 - Google Patents

非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法 Download PDF

Info

Publication number
JP6857185B2
JP6857185B2 JP2018533586A JP2018533586A JP6857185B2 JP 6857185 B2 JP6857185 B2 JP 6857185B2 JP 2018533586 A JP2018533586 A JP 2018533586A JP 2018533586 A JP2018533586 A JP 2018533586A JP 6857185 B2 JP6857185 B2 JP 6857185B2
Authority
JP
Japan
Prior art keywords
biomarker
lung cancer
small cell
cell lung
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018533586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528441A (ja
JP2018528441A5 (enExample
Inventor
ヨンドン キム
ヨンドン キム
ミンギョン ソク
ミンギョン ソク
ジョンハ ジョン
ジョンハ ジョン
エヴァルダス カティリウス，
エヴァルダス カティリウス，
アンソニー ジチ，ドミニク
アンソニー ジチ，ドミニク
エム． オストロフ，レイチェル
エム． オストロフ，レイチェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptamer Sciences Inc
Original Assignee
Aptamer Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptamer Sciences Inc filed Critical Aptamer Sciences Inc
Publication of JP2018528441A publication Critical patent/JP2018528441A/ja
Publication of JP2018528441A5 publication Critical patent/JP2018528441A5/ja
Application granted granted Critical
Publication of JP6857185B2 publication Critical patent/JP6857185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018533586A 2015-09-11 2015-09-11 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法 Active JP6857185B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2015/009552 WO2017043679A1 (en) 2015-09-11 2015-09-11 Protein biomarker panel for detecting non-small cell lung cancer and method for diagnosing a non-small cell lung cancer by the use thereof

Publications (3)

Publication Number Publication Date
JP2018528441A JP2018528441A (ja) 2018-09-27
JP2018528441A5 JP2018528441A5 (enExample) 2021-03-25
JP6857185B2 true JP6857185B2 (ja) 2021-04-14

Family

ID=58239995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018533586A Active JP6857185B2 (ja) 2015-09-11 2015-09-11 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法

Country Status (4)

Country Link
JP (1) JP6857185B2 (enExample)
KR (2) KR102087373B1 (enExample)
CN (1) CN108026584B (enExample)
WO (1) WO2017043679A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3884259A1 (en) * 2018-11-20 2021-09-29 Ventana Medical Systems, Inc. Methods and systems for preparing and analyzing cellular samples for morphological characteristics and biomarker expression
TWI758670B (zh) * 2018-12-24 2022-03-21 奎克生技光電股份有限公司 健康風險評估方法
CN110333341A (zh) * 2019-07-04 2019-10-15 浙江理工大学 一种基于蛋白质芯片技术鉴别丝织品文物样的方法
WO2024173602A2 (en) * 2023-02-14 2024-08-22 The Regents Of The University Of California Systems and methods for automated diagnosis of disease related risk factors in 3d biomedical imaging
WO2025166038A1 (en) * 2024-02-02 2025-08-07 Illumina, Inc. Improved aptamer detection techniques
CN119064600B (zh) * 2024-11-04 2025-01-24 中国科学院生物物理研究所 用于非小细胞肺癌诊断的细胞外囊泡生物标志物及其应用
CN119595908B (zh) * 2024-12-13 2025-10-17 四川大学华西医院 金属离子介导的dna功能纳米机器开关用于双标志物同时检测的分析方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354890B1 (en) * 2000-12-28 2007-08-08 Shionogi & Co., Ltd. Chordin-like polypeptides and dna thereof
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
EP2245199B1 (en) * 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
SI2340506T1 (sl) * 2008-09-09 2016-02-29 Somalogic, Inc. Biomarkerji za pljučni rak in njihove uporabe
WO2013022995A2 (en) * 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CN104535765A (zh) * 2009-03-12 2015-04-22 癌症预防和治疗有限公司 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒
SG168431A1 (en) * 2009-07-23 2011-02-28 Univ Singapore Cancer biomarker and the use thereof
EP2462164A2 (en) * 2009-08-04 2012-06-13 Biosystems International SAS Lung cancer biomarkers
AU2011223789A1 (en) * 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
AU2011274422B2 (en) * 2010-07-09 2016-02-11 Somalogic Operating Co., Inc. Lung cancer biomarkers and uses thereof
BR112013032232A2 (pt) * 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
WO2013033019A1 (en) * 2011-08-31 2013-03-07 University Of Utah Research Foundation Methods for determining the integrity of a biological sample
BR112014000882A2 (pt) 2011-10-24 2017-04-18 Hewlett Packard Development Co Lp dispositivo para ejeção de fluido
CN106168624B (zh) 2011-10-24 2018-03-13 私募蛋白质体公司 肺癌生物标记及其用途
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer

Also Published As

Publication number Publication date
KR20200020958A (ko) 2020-02-26
KR20180036787A (ko) 2018-04-09
KR102087373B1 (ko) 2020-03-10
CN108026584B (zh) 2021-12-10
JP2018528441A (ja) 2018-09-27
WO2017043679A1 (en) 2017-03-16
CN108026584A (zh) 2018-05-11
KR102078310B1 (ko) 2020-02-19

Similar Documents

Publication Publication Date Title
KR101658347B1 (ko) 폐암 바이오마커 및 그것들의 용도
KR101921945B1 (ko) 폐암 바이오마커 및 그것의 용도
KR101870123B1 (ko) 폐암 바이오마커 및 그것의 용도
KR101857462B1 (ko) 췌장암 바이오마커 및 그것의 용도
JP6857185B2 (ja) 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
US20220065872A1 (en) Lung Cancer Biomarkers and Uses Thereof
HK1229002A (en) Lung cancer biomarkers and uses thereof
HK1229002A1 (en) Lung cancer biomarkers and uses thereof
HK1229002B (en) Lung cancer biomarkers and uses thereof
HK1229003A1 (en) Pancreatic cancer biomarkers and uses thereof
HK1229003B (zh) 胰腺癌生物标记及其用途
HK1196429A (en) Lung cancer biomarkers and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180405

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210319

R150 Certificate of patent or registration of utility model

Ref document number: 6857185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250